Pick the best of both glucose and lipid metabolism

Isthmin‐1 is an adipokine that has a potent glucose‐lowering effect by stimulating a common intracellular signaling pathway with insulin through a distinct receptor and has an inhibitory effect on lipogenesis in the liver, whereas insulin has the opposite effect. Isthmin‐1 is expected to have clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Tatsunori, Takahashi, Yuya, Fujita, Hiroki, Waki, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248427/
https://www.ncbi.nlm.nih.gov/pubmed/35212158
http://dx.doi.org/10.1111/jdi.13774
_version_ 1784739359770017792
author Shimizu, Tatsunori
Takahashi, Yuya
Fujita, Hiroki
Waki, Hironori
author_facet Shimizu, Tatsunori
Takahashi, Yuya
Fujita, Hiroki
Waki, Hironori
author_sort Shimizu, Tatsunori
collection PubMed
description Isthmin‐1 is an adipokine that has a potent glucose‐lowering effect by stimulating a common intracellular signaling pathway with insulin through a distinct receptor and has an inhibitory effect on lipogenesis in the liver, whereas insulin has the opposite effect. Isthmin‐1 is expected to have clinical benefits in the treatment of diabetes.[Image: see text]
format Online
Article
Text
id pubmed-9248427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92484272022-07-05 Pick the best of both glucose and lipid metabolism Shimizu, Tatsunori Takahashi, Yuya Fujita, Hiroki Waki, Hironori J Diabetes Investig Commentaries Isthmin‐1 is an adipokine that has a potent glucose‐lowering effect by stimulating a common intracellular signaling pathway with insulin through a distinct receptor and has an inhibitory effect on lipogenesis in the liver, whereas insulin has the opposite effect. Isthmin‐1 is expected to have clinical benefits in the treatment of diabetes.[Image: see text] John Wiley and Sons Inc. 2022-03-08 2022-07 /pmc/articles/PMC9248427/ /pubmed/35212158 http://dx.doi.org/10.1111/jdi.13774 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentaries
Shimizu, Tatsunori
Takahashi, Yuya
Fujita, Hiroki
Waki, Hironori
Pick the best of both glucose and lipid metabolism
title Pick the best of both glucose and lipid metabolism
title_full Pick the best of both glucose and lipid metabolism
title_fullStr Pick the best of both glucose and lipid metabolism
title_full_unstemmed Pick the best of both glucose and lipid metabolism
title_short Pick the best of both glucose and lipid metabolism
title_sort pick the best of both glucose and lipid metabolism
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248427/
https://www.ncbi.nlm.nih.gov/pubmed/35212158
http://dx.doi.org/10.1111/jdi.13774
work_keys_str_mv AT shimizutatsunori pickthebestofbothglucoseandlipidmetabolism
AT takahashiyuya pickthebestofbothglucoseandlipidmetabolism
AT fujitahiroki pickthebestofbothglucoseandlipidmetabolism
AT wakihironori pickthebestofbothglucoseandlipidmetabolism

Ejemplares similares